Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779340 | 1.00 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30781736 | 1.00 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL10071038 | 0.91 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL5497604 | 0.90 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14612149 | 0.89 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL27984222 | 0.88 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL16360194 | 0.88 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2TNF | |
| Hydrochloric Acid SCHEMBL28086829 | 0.87 | KMT2A (0.53) | KMT2AFABP5FABP7EPHX2TNF | |
| SCHEMBL4839280 | 0.87 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL3623157 | 0.87 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018115421-A1 | COMPOUNDS USEFUL FOR TREATING A MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI INFECTION | INTERVET INTERNATIONAL B.V. (NL) | 2018-06-28 | — | — | WO | disclosed |
| US-9822112-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-14 | — | — | US | disclosed |
| US-20170240599-A1 | A PROCESS FOR THE PREPARATION OF LINACLOTIDE | SURESH KUMAR VADLAMANI (IN) | 2017-08-24 | — | — | US | disclosed |
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-9688694-B2 | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9676775-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170057959-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-03-02 | — | — | US | disclosed |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | UNIVERSITY OF MASSACHUSETTS | 2017-02-16 | — | — | US | disclosed |
| US-8883963-B2 | Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities | CADILA HEALTHCARE LIMITED (IN) | 2014-11-11 | — | — | US | disclosed |
| US-8852599-B2 | Immunoconjugates, compositions for making them, and methods of making and use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-07 | — | — | US | disclosed |
| US-8841413-B2 | Antidiabetic compounds | CADILA HEALTHCARE LIMITED (IN) | 2014-09-23 | — | — | US | disclosed |
| US-20130225488-A1 | Antidiabetic Comppounds | CADILA HEALTHCARE LIMITED (IN) | 2013-08-29 | — | — | US | disclosed |
| US-20120270811-A1 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-10-25 | — | — | US | disclosed |
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | UNIVERSITE DE MONTREAL (CA) | 2012-04-26 | — | — | US | disclosed |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | BRACCO IMAGING SPA (IT) | 2012-02-23 | — | — | US | disclosed |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
| US-7312306-B2 | Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240599-A1 | A PROCESS FOR THE PREPARATION OF LINACLOTIDE | LPO, LTB4R2, LTA4H | KMT2A 2672/4885FABP5 3212/4885FABP7 3598/4885 |
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | KMT2A 934/4885FABP5 3508/4885FABP7 1511/4885 |
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | GABRA1, GABRA2, GABRA3 | KMT2A 978/4885FABP5 2504/4885FABP7 616/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KMT2A 327/4885FABP5 4857/4885FABP7 4752/4885 |
| US-20130225488-A1 | Antidiabetic Comppounds | GLP1R, GPR119, GIPR | KMT2A 3912/4885FABP5 728/4885FABP7 807/4885 |
| US-20170057959-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | KMT2A 934/4885FABP5 3508/4885FABP7 1511/4885 |
| US-20120270811-A1 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY | SDF4, CALCB, CALCA | KMT2A 4667/4885FABP5 158/4885FABP7 87/4885 |
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | QPCT, GLUL, ASNS | KMT2A 4277/4885FABP5 3472/4885FABP7 2914/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | KMT2A 327/4885FABP5 4856/4885FABP7 4747/4885 |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | DCLRE1B, RTCB, RNASE1 | KMT2A 4018/4885FABP5 1967/4885FABP7 533/4885 |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | GLP1R, GPR119, GIPR | KMT2A 3541/4885FABP5 1018/4885FABP7 809/4885 |
| US-20120045393-A1 | LHRH-II PEPTIDE ANALOGS | LHCGR, GNRHR, FSHR | KMT2A 510/4885FABP5 1254/4885FABP7 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.